Meddenovo Drug Design

0 reviews

Meddenovo Drug Design specializes in accelerating pharmaceutical research and development through advanced computational biochemistry techniques, with a particular focus on cyclic peptides. By integrating artificial intelligence with physical computational methods, Meddenovo offers innovative solutions tailored to the unique challenges of drug discovery. Their technology platform is designed to enhance efficiency and reduce costs, potentially decreasing drug discovery expenses by up to 30%. Founded by academics with over a decade of experience in drug design and biomolecular modeling, Meddenovo aims to bridge the gap between computational chemistry and experimental research, facilitating collaborative drug discovery efforts. Key Features and Functionality: - Mexa Screen: A cloud-based computational chemistry software that simplifies in silico testing of cyclic peptides. It calculates binding affinities and drug-like properties, allowing researchers to test hypotheses before committing laboratory resources. Mexa Screen offers an intuitive interface with automated preparation steps and AI-driven interpretations, delivering expert-level results without requiring specialized expertise. - Mexa Design: An AI-powered platform that generates optimized cyclic peptide drug candidates from scratch, even in the absence of experimental leads. It employs structure-based rational drug design, expanding the chemical space to include non-canonical amino acids, and ensures the synthesizability of candidates. Mexa Design provides researchers with 15 optimized drug-like candidates tailored to their target of interest. Primary Value and Problem Solved: Meddenovo addresses the significant challenge in drug discovery of efficiently designing and testing novel cyclic peptide therapeutics. By leveraging AI and computational chemistry, their platforms reduce the time and cost associated with traditional drug development processes. This approach enables researchers to rapidly identify and optimize potential drug candidates, accelerating the path from concept to clinical trials and ultimately bringing effective therapies to market more swiftly.